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Adrenergic drugs acting through the h2-adrenoceptor (h2-AR) adenylate cyclase (AC) signal transduction system elicit a variety of
responses within the mammalian airway epithelium; however, its composition of multiple phenotypically differentiated cell types complicates
the understanding of the regulation cascades within this tissue. The present study evaluates h2-AR mRNA level, number, subtype and the
cyclic adenosine-3V,5V-monophosphate (cyclic AMP) response to isoproterenol (iso) in the human airway epithelial cell lines 16HBE14o,
Calu-3 and A549, using reverse transcriptase polymerase chain reaction (RT-PCR), radioligand binding studies, [3H]-radioimmunoassay and
immunocytochemical staining.
After 4–5 days in culture, all three cell types produced h2-AR mRNA and protein at a magnitude of gene expression levels Calu-
3z 16HBE14o>A549, whereas control cells Cos-1 and Caco-2 were negative. The h2-AR adenylate cyclase system was highly expressed
and functional in the human airway epithelial cells Calu-3 and 16HBE14o. The mean h2-AR density (Bmax), equilibrium dissociation
constant (KD), and the percentage of h-AR subtypes assessed by radioligand binding were approximately 9908F 1127 and 6423F 895
binding sites/cell, 32F 2.7 pM and 25F 1.1 pM, and approximately 100% in Calu-3 and 16HBE14ocells, respectively. However, in the
alveolar cell type A549 the cell surface h2-AR was virtually undetectable by ( )-[125I]-iodocyanopindolol (ICYP) binding. Stimulation of
cultured cells with ( )-isoproterenol enhanced the basal cyclic AMP accumulation only in Calu-3 and 16HBE14o cells, which was
blocked by the h2-selective antagonist ICI 118,551, but not by the h1-selective antagonist CGP 20712A, confirming functional coupling of
the h2-AR to adenylate cyclase in these cells. Immunocytochemical staining localised the receptor on the cell membrane and the cytoplasm in
Calu-3 and 16HBE14o cells, while it was confined to the cytoplasm only in A549 cells. In conclusion, the h2-AR expression and its
functional coupling to adenylyl cyclase was very high in the human airway epithelial cells Calu-3 and 16HBE14o, but not in A549,
suggesting that the cell lines Calu-3 and 16HBE14o present suitable models to study function and regulation of the h-adrenoceptor
signalling in the respiratory system.
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1. Introduction studies have shown that bronchial epithelial cells may beh2-Adrenoceptor agonists are the most widely used
bronchodilator drugs in the treatment of obstructive respi-
ratory diseases like asthma [1]. Primarily, they elicit relax-
ation of airway smooth muscle, but their effects may include
a stabilisation of inflammatory cells [2]. A number of0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: gabraham@rz.uni-leipzig.de (G. Abraham).an additional target of h2-AR agonists because they are
involved in the pathophysiology of asthma and, at the same
time, can be influenced by h2-AR agonists [3,4].
The lung epithelium is an important part of the nonspe-
cific defence mechanism in the respiratory system also in
allergen-induced airway hyperreactivity [5,6] and can mod-
ulate the underlying smooth muscle cell metabolism [7].
Lung epithelial cells have the capacity for releasing anti-
inflammatory mediators and inactivation of pro-inflamma-
tory mediators. They may thus initiate and perpetuate
inflammatory reactions by recruitment of inflammatory
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inflammatory or parenchymal cells, and thus determine the
severity of airway disorders.
These activities, including the secretion of mediators
provided by lung epithelial cells, are mediated in an intra-
cellular second messenger-dependent manner by the cyclic
adenosine monophosphate (cAMP), which is in turn selec-
tively activated by the h2-AR G-protein adenylate cyclase
system [5]. The h2-AR G-protein adenylate cyclase system,
which is stimulated by endogenous catecholamines and h2-
AR agonists, is accepted to facilitate clearance of alveolar
fluid, to influence ion fluxes (Na+- and K+-channels), and to
modulate the release of bronchodilating mediators such as
prostaglandin E2 and nitric oxide [8,9]. The ability to raise
intracellular cAMP via the h2-AR might be involved in anti-
inflammatory cascades, since drugs that elevate intracellular
cAMP, such as selective h2-AR agonists and phosphodies-
terase inhibitors, decrease pro-inflammatory cytokines and
chemokines [10,11].
The h2-AR, but not the h1-AR, are known to be
expressed at high density within the lung on multiple
cell types, including bronchial smooth muscles, bronchial
epithelial cells and multiple immune cells [12,13]. There-
fore, it remains difficult to assign the observed physio-
logical and pathophysiological responses following beta-
adrenergic stimulation to a single cell type and to
resolve the complex regulatory pathways. On the other
hand, the only permanent lung epithelial cell culture
model that has been carefully investigated with regard
to h2-AR expression and function is the BEAS-2B cell
line [14]. Other cell lines have been used to investigate
the influence of h-agonists and glucocorticoids without
precise knowledge about receptor functionality [15–17].
Therefore, the aim of the present study was to system-
atically evaluate the frequently used permanent human
lung epithelial cell lines Calu-3, 16HBE14o and A549
with regard to expression of h2-AR mRNA, protein and,
most importantly, the receptor coupling to adenylate
cyclase, the enzyme which activates the intracellular
cAMP formation.2. Materials and methods
2.1. Materials
( )-[125I]-Iodocyanopindolol (ICYP; specific activity,
81.4 TBq mmol 1) was purchased from Perkin-Elmer Life
Sciences (Zaventem, Belgium). CGP 20712A [1-[2-((3-
carbamoyl-4-hydroxy)phenoxy)ethylamino]-3-[4-(1-me-
thyl-4-trifluoromethyl-imidazolyl)-phenoxy]-2-propanol],
(F )-CGP 12177 [(F )-4-(3-tertiarybutylamino-2-hydroxy-
propoxy)-benzimidazole-2-ol], ( )-isoproterenol bitartrate
and 3-isobutyl-1-methylxanthine (IBMX) were obtained
from Sigma-Aldrich-Chemie (Deisenhofen, Germany).
[3H]-cAMP-Radioimmonoassay-Kit was purchased fromAmersham-Buchler (Braunschweig; Germany). Other sub-
stances were obtained at p.A. quality from commercial
sources. The SV40-transformed human bronchial lung cell
line 16HBE14o was obtained from Dieter C. Gruenert
(Department of Medicine, University of Vermont, Burling-
ton, VT) and used at passages 2.88 to 2.98. The number
before the dot gives information about the number of
passages prior, and the last two digits describe the number
of passages after immortalisation. Caco-2, Calu-3, Cos-1,
and A549 were from ATCC (Manassas, VA). FluorSave
anti-fade medium was purchased from Calbiochem (Schwal-
bach, Germany).
2.2. Cell lines and culture conditions
16HBE14o and Calu-3 cells were grown in Eagle’s
minimum essential medium (EMEM) and Caco-2 in Dul-
becco’s modified essential medium (DMEM), both supple-
mented with 10% fetal calf serum, 0.1 mM nonessential
amino acids and 2 mM L-glutamine at 37 jC in 5% CO2.
EMEM with 10% FCS was used for A549 and Cos-1 cell
culture.
2.3. Preparation of mRNA and reverse transcriptase
polymerase chain reaction (RT-PCR)
Total RNA was prepared from 106 freshly trypsinized
cells using the Qiagen RNeasy mRNA Mini-Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. On-column DNase I digestion was applied to mini-
mize contamination with genomic DNA. The quality of the
isolated RNA was controlled by agarose gel electrophoresis
and the RNA concentration was determined spectrophoto-
metrically at 260 nm. Omniscript Reverse Transcriptase
(Qiagen) was used as suggested by the supplier to transcribe
equal amounts of total RNA (1 Ag) into cDNA. Aliquots (1
Al) of the different cDNAs were analyzed for the presence of
h2-AR sequences by PCR using sense (TCGTCATGTC-
TCTCATCGTC) and anti-sense primers (AATGGCA-
TAGGCTTGGTTCG) previously published by Kelsen et
al. [14]. The samples were amplified in an Applied Bio-
systems GeneAmp 9700 thermal cycler in reaction volumes
of 25 Al containing 1.25 U Taq DNA polymerase, 0.1 mM
dNTPs (both Peqlab, Erlangen, Germany) and 0.5 AM of
each primer in 10 mM Tris–HCl (pH 8.8), 50 mM KCl and
1.5 mM MgCl2. After initial denaturation at 94 jC for 3
min, a 25- or 30 cycle-program of 94 jC for 30 s, 56 jC for
30 s and 72 jC for 1 min was followed. The identity of the
amplified product was confirmed by TA cloning into pCR4
TOPO, followed by sequencing (IZKF Leipzig, DNA serv-
ices unit). Sense (ACCACAGTCCATGCCATCAC) and
anti-sense (TCCACCACCCTGTTGCTGTA) primers
detecting glycerol-3-phosphate dehydrogenase (G3PDH)
were used as positive control (30 cycles). DNA size stan-
dard III (Peqlab) was used to determine the sizes of the
products, which were identical with the expected values.
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The number of surface h2-adrenoceptors (Bmax) and the
dissociation constant (KD) were measured on intact lung
epithelial cells by the radioligand binding technique, using
the h-AR antagonist ( )-[125I]-iodocyanopindolol (ICYP)
with high h2-subtype selectivity as recently described by
Abraham et al. [18]. For this purpose, cells were trypsinized
and washed twice in phosphate buffered saline solution
(PBS) and pellets were resuspended in incubation buffer
(10 mM Tris–HCl, 154 mM NaCl, 0.55 mM ascorbic acid,
pH 7.4 at 25 jC). Cell count and viability were determined
by trypan blue exclusion. Saturation of radioligand binding
was determined by incubating aliquots of 105 cells (in 150
Al of incubation buffer) in disposable polypropylene tubes
with six different concentrations of ICYP, ranging from 10
to 150 pM in a total volume of 250 Al for 90 min at 37 jC
in a shaking water bath. In parallel, nonspecific binding
was measured by displacement of ICYP with 1 AM of the
hydrophilic nonselective h-AR antagonist (F )-CGP 12177.
The reactions were terminated by dilution with 10 ml of ice-
cold 10 mM Tris–HCl, 154 mM NaCl buffer, pH 7.4,
followed by rapid filtration over pre-soaked Whatman GF/
C glass fibre filters (Whatman, Inc., Clifton, NJ) using a
Millipore cell harvester. Filters were washed with additional
10 ml of ice-cold Tris–HCl buffer. The radioactivity of the
wet filters was counted with a gamma counter (1470
WIZARD Automatic Gamma Counter, Perkin-Elmer Life
Sciences) at an efficiency of about 80%. ‘‘Specific binding’’
of ICYP was defined as difference between total binding
and nonspecific binding and usually amounted to about 90%
of the total binding at a concentration of radioligand equal to
the KD value. At low receptor densities, specific binding
decreases steadily and was approximately 10% for h2-AR
negative cells (A549, Cos-1, Caco-2). Intracellular ICYP
binding was evaluated using the lipophilic propranolol
instead of CGP 12177. All measurements were performed
at least twice and in duplicate.
To assess the percentage of h1- and h2-adrenoceptor
subtypes, displacement experiments were performed with
constant concentrations of ICYP (40 pM) and 8 to 22
different concentrations (10 10 to 10 4 M) of h-adrenergic
subtype selective competing antagonists (ICI 118,551 as h2-
and CGP 20712A as h1-selective antagonist). Nonspecific
binding was determined in the presence of 1 AM (F )-CGP
12177. The reaction was stopped by adding ice-cold Tris–
HCl buffer and rapid separation of the reaction mixture as
described above.
2.5. Intracellular cyclic AMP production
To determine whether the expressed h-adrenoceptors are
functional, the isoproterenol-induced cAMP accumulation
was further assayed in intact cultured cells. In brief, har-
vested cells were washed with PBS and adjusted to a density
of 200,000 cells/tube. Cell suspensions were incubated for15 min at 37 jC in PBS containing phosphodiesterase
inhibitor 3-isobutyl-1-methylxanthine (IBMX; 100 AM) in
the presence or absence isoproterenol in five different
concentrations ranging from 10 9 to 10 5 M in a final
volume of 330 Al. In addition, isoproterenol-stimulated
cyclic AMP was measured in the presence and absence of
a selective h2-adrenoceptor antagonist ICI 118,551 (100
nM) or a selective h1-adrenoceptor antagonist CGP 20712A
(300 nM). Basal levels of cAMP accumulation were deter-
mined in PBS for each treatment. Incubation was terminated
by placing the incubation tubes in boiling water for 5 min.
After cooling, samples were centrifuged at 12,000 g for
10 min. Cyclic AMP was extracted and measured by
radioimmunoassay (Amersham-Buchler) as described else-
where [19].
2.6. Immunocytochemical staining
For immunocytochemical staining, cells were seeded on
glass cover slips at a density of 50,000 cells/cm2 and grown
for 5 days. Cell layers were fixed for 10 min with 2%
paraformaldehyde, washed with PBS and treated for 10 min
in 50 mM NH4Cl, followed by permeabilization for 8 min
with 0.1% Triton X-100. After 60-min incubation with a
1:100 dilution of a rabbit polyclonal h2-AR antibody, clone
H-73 (Santa Cruz Biotechnology, CA), the layers were
washed three times with PBS and reacted with a 1:200
dilution of FITC-labelled goat anti-rabbit IgG (Sigma) in
PBS containing 1% BSA. Nonspecific staining was evalu-
ated by replacement of the polyclonal h2-AR antibody with
normal rabbit antiserum. After 60-min incubation, the speci-
mens were washed again three times with PBS and embed-
ded in FluorSave anti-fade medium. Images were obtained
by confocal laser scanning microscopy on a Zeiss LSM 510.
2.7. Data analysis
Data reported are meanF S.E. Saturation and competi-
tion binding curves were established by least-square curve
fitting based on the mass action law using the software
GraphPad Prism (GraphPad Software, San Diego, CA).
The maximal number of ICYP binding sites (Bmax) and
the equilibrium dissociation constant (KD) were calculated
from saturation curve fitting for one-site binding model:
Y=Bmax*X/KD +X, where Y as the specific binding, X as
ligand concentration, Bmax as maximum number of binding
sites and KD as the equilibrium binding constant were
defined. For convenience, data were also analyzed from
Scatchard plots [20].
Concentration inhibition curves with antagonist ligands
were obtained from multiple regression analysis with vari-
able hill slope using the iterative nonlinear least-square
curve fitting program GraphPad Prism. The inhibition con-
centrations (IC50 values) for inhibition of binding by com-
peting ligands were calculated from concentration –
inhibition curves which were fitted with the equation Y=
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bition constants (Ki) were calculated from the equation of
Cheng and Prusoff [21]: Ki = IC50/([L]/KD) + 1, where IC50
is defined as the concentration of competing agonist and
antagonist agents required to inhibit 50% of the specific
ICYP binding, [L] the concentration of ICYP in the assay.
The KD values for ICYP were independently estimated from
saturation studies.
Dose response increases to isoproterenol in intracellular
cAMP accumulation were analyzed by fitting the sigmoidal
curves to the experimental data by equating Y=Bottom+
(TopBottom)/1 + 10^((LogEC50X)*Hill Slope)).
The F-ratio test was carried out to determine the signif-
icance of multiple regression and for measurements of the
goodness of fit for either one- or two-site ICYP binding
sites.3. Results
3.1. RT-PCR
Total RNA was obtained from polarized Calu-3 and
16HBE14o as well as 4–5-day-old A549, Cos-1 and
Caco-2 cells. Amplification of complementary cDNA by
PCR over 30 cycles revealed the presence of h2-adrenocep-
tor mRNA in the cell lines Calu-3, 16HBE14o and A549
(Fig. 1). No h2-AR gene expression was observed in Cos-1
fibroblasts and the human adenocarcinoma cells Caco-2,
although all samples produced a comparably strong signal
for G3PDH used as reference (Fig. 1B). An additional PCR
analysis was performed over 25 cycles. In this case, a
positive signal was observed only in Calu-3 and, with
slightly weaker intensity, in 16HBE14o cells, whereas
the cDNA generated from A549 cells remained negative.
This allows to rank the h2-AR mRNA levels in the order:
Calu-3z 16HBE14o>A549.Fig. 1. Analysis of h2-adrenoceptor gene expression by RT-PCR. Total RNA was
transcribed into cDNA and analyzed for (A) h2-adrenoceptor specific sequences by
for G3PDH (B) were used as positive control (30 cycles).3.2. Characteristics of b-adrenoceptors in lung epithelial
cells
3.2.1. b2-Adrenoceptor density
To determine the number of specific ICYP binding
sites on the cell surface of Calu-3, 16HBE14o, and
A549 and, as negative control, on Cos-1 and Caco-2
cells, saturation binding studies were performed with the
labelled h-AR antagonist ( )-[125I]-iodocyanopindolol
(ICYP) and, in parallel, nonspecific binding was deter-
mined in the presence of a non-labelled hydrophilic h-
AR antagonist (F )-CGP 12177 (Fig. 2). The character-
istic ICYP binding pattern suggests the presence of only
a single class of h-ARs in Calu-3 and 16HBE14o cells.
For these cell types, the extrapolated number of maximal
binding sites (Bmax) was 9908F 1127 and 6423F 895,
respectively. Numbers of receptors per cell were calcu-
lated after conversion of specific ICYP binding (cpm, not
corrected for efficiency) in fmol/106 cells and multiplica-
tion with Avogadro’s number. In these cell lines, the
specific ICYP binding was saturable, reversible and of
high affinity with a dissociation constant (KD) of 32F 2.7
and 25F 1.1 pM (Fig. 2, Table 1). Representative
Scatchard plots of the specific ICYP binding are given
in the insets of Fig. 2A and B, which indicate the
presence of one receptor population, i.e. h-AR. Saturation
of specific ICYP binding was obtained at concentrations
between 80 and 150 pM. In contrast, we were not able to
detect specific ICYP binding sites in cell lines A549 and
Cos-1 (Table 1), as the specific ICYP binding was
frequently lower than 10% of the total binding. Similar
data set was found for Caco-2 cells (data not shown).
The lipid-soluble h-AR antagonist propranolol (1 AM)
was used instead of the hydrophilic nonselective h-AR
antagonist (F )-CGP 12177 to displace specifically mem-
brane-bound ICYP regardless of the intracellular local-
isation of the binding sites. Interestingly, A549 cellsisolated from 16HBE14o, Calu-3, A549, Cos-1 and Caco-2 cells, reverse
30 (left) or 25 (right) cycles of amplification as described. Primers specific
Fig. 2. Equilibrium ICYP binding to beta-adrenergic receptors on cultured lung epithelial cell lines, 16HBE14o (A) and Calu-3 (B). 100,000 cells/tube were
incubated for 90 min at 37 jC with six different concentrations of ICYP; total binding (.) and nonspecific binding (o) were quantified from counted wet
filters. Nonspecific binding was defined as the ICYP binding not displaced by 1 AM (F )-CGP 12177. Specific binding (5) was obtained as difference between
total binding and nonspecific binding. Bmax and KD were calculated from specific ICYP binding. Data are means of three separate experiments performed in
duplicate.
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this methodology.
3.2.2. b-Adrenoceptor subtyping
In order to characterize the h-AR subtypes, present in the
human lung epithelial cells under investigation, competitionTable 1
Properties of beta-adrenergic receptors in lung epithelial cells
n Calu-3 16HBE A549 Cos-1
(1) Dissociation constant (KD) and b-adrenoceptor density (Bmax) of
specific ICYP binding
KD (pM) 4 32.12F2.69 25.51F1.08 no BS no BS
Bmax
(binding
sites/cell)
4 9908F1127 6423F895 no BS no BS
(2) Inhibition constants (Ki; nmol/l for selective b-adrenoceptor antagonists
ICI 118.551 and CGP 20712A
ICI 118.551 3 2.07F0.51 1.34F0.36 n.d n.d.
CGP 20712A 3 2760.50F314.50 1431.67F185.30 n.d n.d.
BS: binding sites; n.d.: not determined.studies were performed with several antagonist ligands. In
this study, the radiolabelled ligand for the h-AR (ICYP, 40
pM) was displaced by increasing concentration of non-
labelled highly selective h2-AR antagonist, ICI 118,551,
and selective h1-AR antagonist, CGP 20712A. Representa-
tive displacement curves are shown in Fig. 3. In Calu-3 and
16HBE14o cell lines, both ICI 118,551 and CGP 20712A
inhibited ICYP binding with steep and monophasic compe-
tition curves fitted significantly better to a one-site model
than to a two-site model (F-test: P < 0.01; Fig. 3A and B).
The concentration of ligand causing 50% inhibition of
binding (IC50) was calculated by nonlinear regression anal-
ysis. The IC50 served as an estimate of the displacement
potency of the ligand. This value was inversely related to
the affinity. Based on this calculation, the h2-AR antagonist
ICI 118,551 [22] inhibited ICYP binding with about >1000
times more potency than the h1-AR antagonist CGP
20712A (Table 1; [23]). As shown in Fig. 3, the competition
binding curves of both antagonists for ICYP binding were
similar in Calu-3 and 16HBE14o cell lines, and had
comparable potencies across both cell lines (Table 1). The
inhibition constant (Ki) calculated from the inhibition con-
Fig. 3. Competitive ICYP displacement by the h2- and h1-selective
adrenoceptor antagonists ICI 118,551 and CGP 20712A in 16HBE14o (A)
and Calu-3 (B) cells. Cells were incubated with 40 pM ICYP for 90 min at
37 jC in the absence (100%) or presence of the selective h2-antagonist ICI
118,551 (.) and the selective h1-antagonist CGP 20712A (o) or 1 AM
(F )-CGP 12177 to define nonspecific binding. Data are expressed as the
percentage of total binding in the absence of competing agents and are
means of three experiments, each performed in duplicate.
Fig. 4. Characterization of h-adrenoceptor function: concentration depen-
dent stimulation of cAMP by ( )-isoproterenol in 16HBE14o and Calu-
3, but not in A549 and Cos-1 cells. Production of intracellular cAMP was
stimulated by incubation either with isoproterenol at the indicated
concentrations or without drugs (basal cAMP level) for 15 min at 37 jC.
cAMP was measured in supernatants obtained from lysed cells. Data
represent meansF S.E. of two experiments performed in duplicate.
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2760.50F 314.50 nM for CGP 20712A in Calu-3, and
1.34F 0.36 nM for ICI 118,551 and 1431.67F 185.30
nM for CGP 20712A in 16HBE14o, respectively. In
contrast, high affinity displacement binding curves could
neither be generated with ICI 118,551 nor with CGP
20712A in A549, Cos-1 and Caco-2 cells, suggesting the
absence of surface h-ARs on these cell types.
3.2.3. b-Adrenoceptor function
Further, the function of the expressed h-adrenoceptor
protein was studied at the signal transduction level. For
this purpose, we determined the concentration dependent
stimulation of adenylate cyclase activation by ( )-isopro-
terenol as measured by intracellular cAMP production inall five cell lines. As shown in Fig. 4, treatment with ( )-
isoproterenol in concentrations from 10 9 to 10 5 M for
15 min resulted in a marked and reproducible cAMP
accumulation that increased steeply from basal levels
(7.90F 0.48 pmol/106 cells) up to a maximum cAMP
response. Strong cyclic AMP responses to isoproterenol
were observed only in Calu-3 with 64.61F 0.52 pmol/106
cells and in 16HBE14o cells with 57.07F 2.53 pmol/106
cells, respectively. Cos-1 cells showed significant but very
low cAMP formation in response to isoproterenol (10 AM)
(12.81F 0.26 pmol/106 cells). A549 and Caco-2 cells did
not show detectable cAMP induction. To verify the role of
the h2-AR subtype and its coupling to the adenylate
cyclase in lung epithelial cells, (1 AM) ( )-isoprotere-
nol-stimulated cAMP production was discriminated by the
h2-selective antagonist ICI 118,551 (100 nM) and the h1-
selective antagonist CGP 20712A (300 nM). The h-adren-
ergic agonist isoproterenol (1 AM) acting through h-adre-
noceptors led to an increase in intracellular cAMP
generation with about 275% in Calu-3 cells and 602% in
16HBE14o cells above basal values (Fig. 5). Treatment
of cells with 100 nM ICI 118,551 inhibited completely the
isoproterenol-mediated cAMP response. This h2-selective
antagonist decreased even the cAMP content in Calu-3 and
16HBE14o cells to 86% and 30% below basal values,
respectively (Fig. 5), while pretreatment with the h1-
selective antagonist CGP 20712A (300 nM) had no effect.
In all other cell lines, neither ICI 118,551 nor CGP
20712A affected the cAMP responses to isoproterenol
stimulation (see also Fig. 5).
3.2.4. Immunocytochemical staining
Immunocytochemistry was performed to confirm the
presence of h2-AR protein and to collect evidence for its
Fig. 5. Characterization of h-adrenoceptors function: Inhibition of ( )-isoproterenol-induced intracellular cAMP accumulation in 16HBE14o and Calu-3, but
not in A549 and Cos-1 cells. The activity of adenylate cyclase for cAMP production was determined in the absence (basal) or in the presence of only ( )-
isoproterenol (1 AM) or in the presence of ( )-isoproterenol and the selective h2-antagonist ICI 118,551 (100 nM) or in the presence of ( )-isoproterenol and
the selective h1-antagonist CGP 20712A (300 nM).
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In accordance with mRNA analysis by RT-PCR and
radioligand binding studies, no receptor protein was
detectable in Cos-1 and Caco-2 cells. Staining of A549,
Calu-3 and 16HBE14o, however, resulted in significant
and specific fluorescence (Fig. 6). Interestingly, the fluo-
rescence was apparently confined to the cytoplasm in
A549 cells, while the cell assemblies of Calu-3 and
16HBE14o cultures did stain within the cytoplasm and
along the cell membrane.Fig. 6. Immunocytochemical staining of 16HBE14o, Calu-3 and A549 for h2-adre
with paraformaldehyde, permeabilised with Triton X-100, incubated with a 1:100
dilution of a FITC-labelled goat-anti-rabbit IgG. Images were obtained by confoc4. Discussion
The main findings of the present study were that, in
three permanent human lung epithelial cell lines (Calu-3,
16HBE14o, A549), (1) h2-adrenoceptor mRNA and pro-
tein were produced; (2) ICYP binding studies confirmed
the presence of h-adrenoceptors on the cell surface of
Calu-3 and 16HBE14o, but in A549 cells h-adrenocep-
tors were localized in the cytoplasm. In addition, (3)
competition binding studies showed the presence of anoceptor protein. Cells were grown for 4–5 days on glass cover slips, fixed
dilution of receptor specific polyclonal antiserum and stained with a 1:200
al laser scanning microscopy on a Zeiss LSM 510.
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16HBE14o, which (4) are coupled to adenylate cyclase to
produce typical levels of cAMP in response to h-adrener-
gic agonist stimulation.
Within the normal lung, h2-AR is known to be expressed
not only in the airway smooth muscle but also in epithelial
cell types [24,25]. Previous studies have shown that airway
epithelial cells take part in the pathophysiology and therapy
of obstructive respiratory diseases as they release pro- or
anti-inflammatory mediators [5]. Hence, they may represent
an important target of the class of h2-adrenergic drugs [1,4].
However, no appropriate cell culture models of the airway
epithelium are available except one, the BEAS-2B cell line,
which expresses functional h2-ARs and thus, could give
insight in the underlying mechanisms of h-adrenergic drug
responses. This human bronchial epithelial cell line BEAS-
2B was obtained by immortalization with SV40 from
normal lung tissue [26]. According to Kelsen et al. [14],
this cell line expresses about 4360F 528 surface receptors
per cell and accumulates up to 226 pmol cAMP/106 cells
upon stimulation with 10 AM isoproterenol. Although other
cell lines, including Calu-3, 16HBE14o and A549, have
been employed to study the properties of h-AR agonist
responsiveness [15,16], the mechanisms by which the h-
agonist-mediated phenomena were achieved at cellular
receptor level had not been investigated. The aim of this
study was, therefore, to characterize and identify functional
h-ARs and to follow up the generation of a second mes-
senger in the permanent human epithelial cell lines of the
respiratory system, Calu-3, 16HBE14o, and A549.
The cell line Calu-3 was isolated from an adenocarcino-
ma of the lung and is frequently used in biopharmaceutical
studies. When grown to confluency, this cell line forms a
functional barrier and starts to exhibit properties of differ-
entiated sub-mucosal gland cells [27]. Previous studies
suggested that functional adrenoceptors exist, as treatment
with (nonselective) agonists influenced secretion of defen-
sins [16] and chloride secretion [15]. However, receptor
density, functionality and the receptor subtype that mediate
the response were not known.
16HBE14o was generated by transformation of normal
bronchial epithelial cells with a replication defective
SV40ori [28]. Lectin typing suggests a classification as
basal cell of the bronchial epithelium [29], and indeed, this
line has the ability to form layers with functional tight
junctions, when grown under appropriate culture conditions
[30]. It has previously been used to study the effect of the
nonselective h-AR agonist isoproterenol on chloride ion
conductance [31] and IL-8 release [32]. Receptor subtypes
and the signaling pathway involved were not investigated.
As primary human alveolar epithelial cells are not easily
accessible, the type-II pneumocyte-like A549 tumor cell line
remains the most frequently used model of the alveoli.
Although they express some biochemical features of differ-
entiated tissue, these cells cannot form polarized epithelial
cell assemblies or transform into type-I pneumocytes [33].They have been used to study the regulation of h2-AR
mRNA and protein levels [34,35]. In addition, cell type-
specific effects of cAMP upregulation were postulated
based on the observation that cell growth was stimulated
in 16HBE14o and NCI-292 but not in A549 cells by the
h2-agonist salbutamol [17]. However, conclusions were
drawn without detailed knowledge about receptor localiza-
tion and functional coupling. The results obtained here
would suggest that the observed difference was due to the
fact that A549 cells produce h2-ARs but do not display
these at the cell surface where they should couple to G-
protein and adenylate cyclase and produce cAMP upon
agonist stimulation.
To close this gap in background information, we
carried out the studies described above. RT-PCR analysis
of h2-AR gene expression confirmed that all three lines
do still produce significant levels of h2-AR mRNA.
Interestingly, the amounts detected in the bronchial epi-
thelial cells were considerably higher than those found in
the A549 cells. It remains unclear whether this difference
is reflecting their origin as airway versus alveolar, or is
the result of differentiation.
We further sought to provide confirmation at the protein
level by radioligand binding (ICYP). In Calu-3 and
16HBE14o cell lines, ICYP binding clearly showed the
criteria expected of ligand binding to cell surface h-AR. It
was saturable and reversible and of high affinity (KD value:
28.82 pM), agreeing closely with prior studies of ICYP
binding to h-AR in the lung [24,36] and airway epithelium
[37]. The obtained data demonstrate a high density of h2-
ARs in Calu-3 and 16HBE14o cells with 9908F 1127 and
6423F 895 binding sites/cell (Bmax), respectively. This is
close to the numbers found in human airway epithelial cells
harvested by bronchoscopic procedures in vivo (7000–9000
h2-AR/cell [38,39] and in primary cultures of bovine
bronchial epithelial cells (13000 h2-AR/cell [40]). On the
other hand, the BEAS-2B cell line, which has been used
previously to study the regulation of h2-adrenoceptor–G-
protein–adenylate cyclase system function [41], contained
lower, but well in the range, numbers of h2-ARs (2500 to
4000 receptors/cell) [9,14].
Competitive binding assays employing the h2-selective
adrenoceptor antagonist, ICI 118,551, further showed that
the radioligand ICYP binding to Calu-3 and 16HBE14o
cells was inhibited concentration-dependently by ICI
118,551 with steep monophasic concentration–inhibition
curves, which fitted significantly better to a one-site model
than to a two-site model. These monophasic inhibition
curves favour the presence of one h-adrenoceptor subtype,
the h2-subtype. The data obtained from the concentration–
inhibition curves with the highly h1-selective adrenoceptor
antagonist, CGP 20712A, reconfirmed this finding, as the
affinity of CGP 20712A for the h2-subtype was >1000-fold
lower than that of ICI 118,551. These findings from both
selective h-adrenoceptor antagonists thus provided a ho-
mogeneous population of h2-subtype (f 100%) in Calu-3
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agreement with reports in the literature that the h2-adreno-
ceptors represent the mere binding sites as for both
antagonists. Identical results were found in cardiomyocytes
[42] as well as for ICI 118,551 and betaxolol (h1-selective)
in BEAS-2B cells [9]. In the latter cell type, the presence
of a small number of h1-adrenoceptors ( < 5%) could not be
excluded, since the data obtained were best fit to a two-site
model. In contrast, percentages of h2- and h1-ARs were
80% and 20% in freshly isolated human airway epithelial
cells according to Kelsen et al. [38]. This proportion is
inconsistent with that of Calu-3, 16HBE14o and, as
previously shown, in BEAS-2B. The discrepancy may, at
least in part, be explained by the heterogeneity in the cell
population of the respiratory system. On the other hand,
other studies in primary bovine bronchial epithelial cells
have shown only a homogeneous population of h-ARs of
the h2-subtype [40].
Furthermore, by studying the receptor coupling to adeny-
late cyclase via measurement of cAMP accumulation, it
could be confirmed that the h2-ARs produced in Calu-3 and
16HBE14o cells were functional. Stimulation with the h-
adrenoceptor agonist ( )-isoproterenol induced a signifi-
cant intracellular cAMP accumulation with a maximum of
65 pmol/106 cells in Calu-3 cells and 57 pmol/106 cells in
16HBE14o cells. The magnitude of the response at this
concentration of isoproterenol was similar to that observed
ex vivo and in vivo (40 to 120 pmol cAMP/106 cells
[12,38]). Finally, to show that whether cAMP generation
in response to isoproterenol was mediated by the h2-AR
subtype, inhibition studies with the h2-selective adrenocep-
tor antagonist, ICI 118,551, and the h1-selective adrenocep-
tor antagonist, CGP 20712A, were performed. In Calu-3 and
16HBE14o cells, ICI 118,551 was considerably more
potent than CGP 20712A in reversing agonist-induced
cAMP production. Taken together, the high potency and
selectivity of ICI 118,551 vs. CGP 20712A against the
functional responses of isoproterenol indicate that catechol-
amine-induced effects in Calu-3 and 16HBE14o cells are
mediated through the activation of h2-AR. Additionally, it
was interesting to note that ICI 118,551 inhibited the
isoproterenol-induced cAMP generation even below the
basal values in Calu-3 and 16HBE14o. Presumably, ICI
118,551 seems to act here not as neutral antagonist but
interfered as an inverse agonist so that high levels of h2-AR
expression might aid the detection of inverse agonism for
ligands with a negative intrinsic activity for adenylate
cyclase activity [43]. However, we can, at least in part,
draw a conclusion also from the radioligand binding that the
isoproterenol-induced cAMP responses are mediated by the
h2-adrenoceptor subtype. Among other cell lines studied, in
Cos-1 cells, we were able, even though much lower than in
Calu-3 and 16HBE14o cells, to measure isoproterenol-
stimulated cAMP level. Conversely, however, it was not
possible to detect surface h-ARs by radioligand binding
studies in this cell line. Thus, the data strongly suggest thatthe agonist-stimulated cAMP generation might not be h1- or
h2-adrenoceptor-mediated, as also the h2-selective antago-
nist ICI 118,551 and h1-selective antagonist CGP 20712A
did not have any influence on isoproterenol-induced intra-
cellular cAMP responses. However, there is increasing
evidence for the existence of non-h1- and non-h2-adreno-
ceptors (an atypical h3-adrenoceptor) with their low affinity
for the standard selective h1- and h2-adrenoceptor antago-
nists in different tissues and cells, but h-agonist activation
of these receptors can stimulate intracellular cAMP produc-
tion [44].
In marked contrast to Calu-3 and 16HBE14o cell lines,
ICYP binding did not reveal the presence of membrane-
bound h-ARs in A549, which resemble alveolar type II
pneumocytes. Correspondingly, ( )-isoproterenol facilitat-
ed no functional responsiveness. However, RT-PCR studies
and immunocytochemistry suggested the presence of h2-AR
mRNA and protein, although the latter was seemingly
localized to the cytoplasm of the cells. In fact, evaluation
of intracellular ICYP binding sites by displacement studies
with non-labelled lipophilic h-adrenoceptor antagonist pro-
pranolol (1 AM), instead of the hydrophilic ligand (F )-CGP
12177, revealed approximately 4000 receptors/cell. Hence,
this cell type produces significant amounts of h-ARs, but
does not represent those at the cell surface as binding sites
displaced by the hydrophilic ligands like (F )-CGP 12177.
On the basis of this observation, it can be concluded that
although mRNA and protein are produced, the h2-AR is not
trafficked to the cell membrane in A549 and becomes only
accessible to membrane permeant ligands such as the lipid-
soluble ligand, propranolol, or actively internalized hydro-
philic molecules that are sorted into the corresponding
compartment. Consequently, treatment of A549 cell with
isoproterenol did not stimulate cAMP accumulation. To
date, there is no reliable explanation on the biological
significance of the intracellular h-adrenoceptors found in
A549 cells.
In conclusion, the present study has shown that Calu-3
and 16HBE14o cells express the h2-AR subtype at the cell
surface and that the receptor is, unlike in A549 cells with
only intracellular h2-ARs, efficiently coupled to adenylate
cyclase, resulting in the accumulation of intracellular cyclic
AMP. Hence, Calu-3 and 16HBE14o cells should provide
suitable models for further studies into molecular mecha-
nisms involved in the regulation of h2-AR responsiveness in
airway epithelial cells and its pharmacological modulation
in a variety of physiological and pathophysiological states.
Results obtained by using A549 cells should be interpreted
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